Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris

A technology for coronary atherosclerosis and stable angina pectoris, which is applied in the field of biochemistry to achieve the effects of improving diagnostic convenience, promoting standardization and high sensitivity

Active Publication Date: 2016-03-30
齐炼文
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] No one has used plasma metabolite levels to diagnose coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Screening characterization of differential metabolites in plasma between patients with coronary atherosclerosis and patients with stable angina

[0029] 1. Objects and methods

[0030] 1. Specimen source

[0031] After obtaining the consent of the patients, the peripheral venous blood plasma of 480 patients with coronary atherosclerosis, 280 patients with stable angina pectoris and 350 healthy people in Jiangsu Provincial People's Hospital from September 2010 to June 2015 were collected. Confirmed by coronary angiography. The age and sex of healthy people were matched with patients with coronary atherosclerosis and stable angina pectoris. All patients with coronary atherosclerosis, patients with stable angina pectoris and healthy people have normal heart, lung, liver, kidney and hematopoietic functions.

[0032] The time of blood collection was in the morning on an empty stomach.

[0033] 2. Main reagents

[0034] Acetonitrile and formic acid (UPLC pure)...

Embodiment 2

[0055] Example 2: Construction of ROC curve to verify the ability of 8 differential metabolites to diagnose coronary atherosclerosis and stable angina pectoris

[0056] Receiver operating curve (ROC) method was used for verification, and the expression levels of differential metabolites in the plasma of patients with stable angina pectoris and patients with coronary atherosclerosis were used to diagnose and distinguish patients with stable angina pectoris and patients with coronary atherosclerosis Ability. The results showed that phosphorylcholine, palmitoylethanolamine, phytosphingosine, phosphatidylcholine, ethyl chenodeoxycholine, lysophosphatidylcholine (16:0), lysophosphatidylcholine (18:2) and phosphatidylinositol (20:4 / 0:0), these 8 differential metabolites have a strong ability to diagnose patients with stable angina pectoris and patients with coronary atherosclerosis, and the area under the ROC curve (AUC) is greater than 0.7, which has clinical diagnostic significan...

Embodiment 3

[0065] Embodiment 3: the preparation of detection kit

[0066] A detection kit has been prepared based on the metabolic markers provided by the present invention, and the kit includes the following components:

[0067] Standards for metabolic markers: including phosphorylcholine, palmitoylethanolamine, phytosphingosine, phosphatidylcholine, ethylchenodeoxycholic acid, lysophosphatidylcholine (16:0), lysophosphatidylcholine (18:2) and phosphatidylinositol (20:4 / 0:0), each standard product is packaged separately;

[0068] Plasma metabolite extraction solvent: 100% acetonitrile and 20% acetonitrile aqueous solution (for UPLC-Q / TOF-MS sample preparation); a mixed solution of methanol, chloroform and water in a ratio of 2.5:1:1, methoxyaminopyridine and N-Methyl-N-trimethylsilyl trifluoroacetamide (for GC-Q / MS sample preparation); 20% acetonitrile aqueous solution can be used as dissolved standard in UPLC-Q / TOF-MS screening and characterization Solvent; in GC-Q / MS screening and c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris. The metabolite marker includes one or more of phosphorylcholine, palmitoylethanolamine, phytosphingosine, phosphatidylcholine, ethyl chenodeoxycholic acid, lysophosphatidyl choline (16:0), lysophosphatidyl choline (18:2) and phosphatidyl inositol (20:4 / 0:0). When the single metabolite marker is used for diagnosing and distinguishing a patient suffering from the stable angina pectoris and a patient suffering from the coronary atherosclerosis, the ROC areas under the curve (AUC) are greater than 0.7, and the marker has clinical diagnostic significance. When the markers are combined for diagnosis, the AUC is further improved with the increase of the combination number; when all eight markers are combined, the AUC is the highest and is up to 0.985, and the sensitivity and specificity are 97.4% and 98.0% respectively under the condition of an optimal cutoff value. The metabolite marker can accurately diagnose and distinguish the coronary atherosclerosis and the stable angina pectoris and is high in accuracy and good in sensitivity and specificity.

Description

technical field [0001] The invention belongs to the field of biochemistry and relates to metabolic markers for diagnosis and classification of coronary heart disease, in particular to a group of metabolic markers for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris. Background technique [0002] Coronary heart disease, also known as ischemic heart disease, involves atherosclerosis in the arteries supplying myocardial blood, that is, coronary atherosclerotic lesions cause vascular lumen narrowing or plaque formation or even rupture and complete blockage, resulting in myocardial ischemia and hypoxia. Or necrosis leads to cardiac ischemic disease, which leads to a series of serious cardiovascular events such as clinical angina pectoris and myocardial infarction. Coronary heart disease is the main killer of human health. It has the characteristics of high incidence rate, high disability rate, high recurrence rate, high mortality rate, and many co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/88G01N30/06
CPCG01N30/02G01N33/50G01N30/88G01N30/06
Inventor 齐炼文朱伟秦勇陈彦
Owner 齐炼文
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com